This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
pd-1
PD-1
Programmed death receptor 1 (CD279); inhibitory checkpoint on activated T cells. PD-L1 binding recruits SHP-2, dephosphorylating TCR intermediates and suppressing CTL cytotoxicity. Blocked by pembrolizumab/nivolumab — approved immunotherapy in NSCLC, melanoma, and 40+ cancers.
Entry Metadata
| Field | Value |
|---|---|
| ID | pd-1 |
| Name | PD-1 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895. · PubMed 1396582
- Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. · PubMed 12091876
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. · PubMed 22658127